Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
Keywords:
Tags: Pharmaceutical,
As sales growth slows in developed countries, pricing drops, and drug development is weak, the search for new avenues for growth.
Grouped Articles
Glaxo's Garnier Is Taking the Heat
Wall Street Journal 07/09/2007
Glaxo to Weigh Results Of New Diet Pill
Wall Street Journal 10/24/2007
Prescription-Drug Sales Growth Is Expected to Slow
Wall Street Journal 11/01/2007
BusinessWeek 12/05/2007
Osteoporosis Drug Is Amgen's Hope For a Strong Future
Wall Street Journal 12/14/2007
Glaxo Becomes Master of Reinventing Drugs
Wall Street Journal 04/17/2008
Will drug innovation be affected adversely by price reductions in the USA? No say experts as it is a globalized industry and innovation takes place in labs around the world. And the pricing reforms, as in Britian and Germany, can actually encourage R&D for effective drugs with good cost relationships; when comparitive effectiveness of drugs and cost benefit analyses is used in pricing reforms. Pricing of pharmaceutical products and healthcare services is the major unsolved problem in the U.S.
Grouped Articles
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
New Medicines Emerge, but Few Blockbusters
Wall Street Journal 12/16/2013
New York Times 12/21/2013
FDA Approves Cholesterol Drug From Regeneron, Sanofi
Wall Street Journal 07/25/2015
Washington Post 09/22/2015
Settlement May Cut Drug Prices
Wall Street Journal 06/09/2007
The cost of most healthcare services are double or higher in the U.S. than in Canada, Germany, France and Japan. By not bringing prices in line with the price in other major developed countries, the U.S. is effectively defunding infrastructure, R&D, education and other important means of improving competitiveness say experts. The methods of setting price present in these countries are notably absent in the U.S. The Obama healthcare bill and before that the Bush Medicare Prescription Drug Benefit simply leave this problem unaddressed.
Grouped Articles
Cuts Would Only Shift Health-Care Costs
Wall Street Journal 07/13/2011
Bayonne Medical Center Has Highest U.S. Billing Rates
New York Times 05/16/2013
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
New York Times 12/21/2013
Economy Led to Cuts in Use of Health Care, Study Says
New York Times 08/16/2010
Washington Post 09/22/2015
The settlements also involve drug pricing and marketing.
Grouped Articles
Drug Firms Curb Ties to Doctors
Wall Street Journal 12/18/2013
In Guilty Plea, OxyContin Maker to Pay $600 Million
New York Times 05/10/2007
Glaxo Sues Abbott Labs Over AIDS Drug Pricing
Wall Street Journal 11/09/2007
Drug Companies Face Political, Scientific Attacks
Wall Street Journal 01/23/2008
Drug Industry to Announce Revised Code on Marketing
New York Times 07/10/2008
Drug Approval Is Not a Shield From Lawsuits, Justices Rule
New York Times 03/05/2009
The costs of American health care per patient is double that of some European countries with poorer results in many critical areas of medical services. The burden on society as a whole and the lack of incentive for providers and patients to take action. Pricing of healthcare and pharmaceuticals as the major unsolved problem in the U.S.
Grouped Articles
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
New York Times 12/21/2013
Economy Led to Cuts in Use of Health Care, Study Says
New York Times 08/16/2010
Patients’ Costs Skyrocket; Specialists’ Incomes Soar
New York Times 01/18/2014
A grim diagnosis for our ailing U.S. health care system - The Washington Post
Washington Post 11/28/2011
Four Deficit Myths and a Frightening Fact
Wall Street Journal 01/19/2012
Higer cost of specialty drugs for cancer, MS, other diseases, and the efforts by companies to squeeze profits from a shrinking branded portfolio push costs up for branded drugs. Prices of generics decline significantly. Express Scripts study shows 11% increase for branded drugs in 2011-2012 compared to 22% decrease for generics.
Grouped Articles
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Will Rising Prices for Some Generic Drugs Never End?
Wall Street Journal 11/14/2014
Washington Post 09/22/2015
Cost of Brand-Name Prescription Medicines Soaring
New York Times 11/28/2012
Beneath Budget Battle, a Health-Spending Juggernaut
Wall Street Journal 12/17/2012
Efforts by companies like GlaxoSMithKline to meet cost concerns of governments by linking pricing to the effectiveness of the drugs or treatments. Pharmaceutical pricing an issue with governments.
Grouped Articles
Wall Street Journal 11/09/2006
Glaxo Chief Charts New Growth Strategy
Wall Street Journal 06/10/2008
Pricey Drugs Put Squeeze on Doctors
Wall Street Journal 07/08/2008
Drug Makers Trim Prices for Health Overhaul
Wall Street Journal 06/22/2009
For Drug Makers, Concessions Have a Bright Side
Wall Street Journal 06/23/2009
New York Times 06/25/2009
The pricing of pharmaceutical products and healthcare services in the U.S. and Europe.
Grouped Articles
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
Glaxo Sues Abbott Labs Over AIDS Drug Pricing
Wall Street Journal 11/09/2007
India Prepares EU Trade Complaint
Wall Street Journal 08/06/2009
Democrats Say No to Cost Cap for Drug Makers
New York Times 08/07/2009
Economist 08/27/2009
Large Price Jumps Reported for Small but Vital Drugs
New York Times 01/11/2010
Merck sells Vytorin a combination of Zocor and Zetia for a expensive price touting benefits that may not exist according to its own study when generic Zocor can be bought for $6 for 30 days supply.
Grouped Articles
Stakes Remain High in Merck, Schering-Plough Drug Study
Wall Street Journal 12/17/2007
Drug Has No Benefit in Trial, Makers Say
New York Times 01/14/2008
Study Missteps Threaten Turnaround at Schering
Wall Street Journal 01/17/2008
Heart Group Backs Drug Made by Ally
New York Times 01/24/2008
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Anemia drug made billions, but at what cost? - The Washington Post
Washington Post 07/20/2012
The pricing practices for healthcare and pharmaceutical products in Europe during the eurozone debt crisis. Government initiative to limit pricing.
Grouped Articles
Austerity in Europe Puts Pressure on Drug Companies
New York Times 02/23/2012
Why an MRI costs $1,080 in America and $280 in France - The Washington Post
Washington Post 03/05/2012
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Europe Drug Makers Seek Deal on Crisis Pricing
Wall Street Journal 06/25/2012
Large Price Jumps Reported for Small but Vital Drugs
New York Times 01/11/2010
New solutions are being developed and new ideas being tried to bring down health care costs. In many case quality can improve at lower cost or the similiar results delivered for lower cost with some other advantages inpatient focussed healthcare that improve outcomes. Pricing of pharmaceutical products and healthcare services as the major unsolved problem in the U.S.
Grouped Articles
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
New York Times 12/21/2013
Economy Led to Cuts in Use of Health Care, Study Says
New York Times 08/16/2010
Digital Records May Not Cut Health Costs, Study Cautions
New York Times 03/05/2012
Health Care: Obama's Budget Skimps on Cost-Cutting
BusinessWeek 03/05/2009
Hospitals Merge Design and Building to Cut Costs
New York Times 04/15/2009
The rising costs of the French system and its concept and performance. Efforts to meet rising costs and rise of the "mutuals." Healthcare in France is at about 11% of GNP compared to 16% in the USA, with 50 million uninsured in the US and 99% of 64 million people of France covered. Pricing of pharmaceutical products and healthcare services remains a major unsolved problem in the U.S.
Grouped Articles
The Soaring Cost of a Simple Breath
New York Times 10/12/2013
New York Times 12/21/2013
The French Lesson in Health Care
BusinessWeek 06/28/2007
New York Times 07/14/2007
In Holland, Some See Model For U.S. Health-Care System
Wall Street Journal 09/06/2007
Maker of Lipitor Digs In to Fight Generic Rival
New York Times 11/03/2007
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1